Notable examples among these would be targeting HER2 mutations with trastuzumab + tucatinib ± fulvestrant,31 using pembrolizumab in tumors with high tumor mutational burden,32 or using PARP inhibitors in tumors with somatic BRCA1/2 or germline PALB2 mutations,33 as well as combining endocrine therapy with PARP inhibitors in BRCA‐mutated and hormone receptor positive tumors (currently, phase II ELEMENT study, NCT06201234). The gene discussed is ERBB2; the disease is neoplasm.